Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Key Inclusion Criteria:

• Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previouslyImmunomedics)-sponsored parent study.

• Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy.

Key Exclusion Criteria:

• Females who are pregnant or lactating.

• Initiated therapy with another cancer therapeutic agent since receiving last dose ofstudy drug on the parent study in which they participated.

• Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanentdiscontinuation of therapy.

• Have other concurrent medical or psychiatric conditions that, in the Investigator'sopinion, may be likely to confound study interpretation or prevent completion ofstudy procedures and follow-up examinations.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.